CN111358891A - Immune activation spray and preparation method thereof - Google Patents
Immune activation spray and preparation method thereof Download PDFInfo
- Publication number
- CN111358891A CN111358891A CN202010242232.3A CN202010242232A CN111358891A CN 111358891 A CN111358891 A CN 111358891A CN 202010242232 A CN202010242232 A CN 202010242232A CN 111358891 A CN111358891 A CN 111358891A
- Authority
- CN
- China
- Prior art keywords
- leaching
- rhizoma polygonati
- yeast
- rhizoma
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007921 spray Substances 0.000 title claims abstract description 33
- 230000005934 immune activation Effects 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title abstract description 28
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 78
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 36
- 241000132012 Atractylodes Species 0.000 claims abstract description 22
- 239000006184 cosolvent Substances 0.000 claims abstract description 17
- 239000003995 emulsifying agent Substances 0.000 claims abstract description 17
- 239000003755 preservative agent Substances 0.000 claims abstract description 17
- 230000002335 preservative effect Effects 0.000 claims abstract description 16
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 15
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940116229 borneol Drugs 0.000 claims abstract description 15
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000001738 pogostemon cablin oil Substances 0.000 claims abstract description 12
- 230000002421 anti-septic effect Effects 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 10
- 238000002386 leaching Methods 0.000 claims description 92
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 84
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 75
- 238000001914 filtration Methods 0.000 claims description 40
- 239000000725 suspension Substances 0.000 claims description 21
- 238000004140 cleaning Methods 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 20
- 238000002791 soaking Methods 0.000 claims description 20
- 239000007788 liquid Substances 0.000 claims description 15
- 241000092665 Atractylodes macrocephala Species 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 239000000839 emulsion Substances 0.000 claims description 10
- 238000000855 fermentation Methods 0.000 claims description 10
- 230000004151 fermentation Effects 0.000 claims description 10
- 230000001954 sterilising effect Effects 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
- 239000008103 glucose Substances 0.000 claims description 9
- 241001529821 Agastache Species 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 238000007865 diluting Methods 0.000 claims description 5
- 239000003921 oil Substances 0.000 claims description 5
- 238000004806 packaging method and process Methods 0.000 claims description 5
- 239000003814 drug Substances 0.000 abstract description 24
- 230000036039 immunity Effects 0.000 abstract description 17
- 230000003213 activating effect Effects 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 241000411851 herbal medicine Species 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 3
- 208000035240 Disease Resistance Diseases 0.000 abstract description 2
- 238000012545 processing Methods 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 57
- 150000004676 glycans Chemical class 0.000 description 21
- 229920001282 polysaccharide Polymers 0.000 description 20
- 239000005017 polysaccharide Substances 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 19
- 238000005507 spraying Methods 0.000 description 19
- 241000700605 Viruses Species 0.000 description 18
- 230000000694 effects Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000002345 respiratory system Anatomy 0.000 description 10
- 238000011160 research Methods 0.000 description 9
- 230000000840 anti-viral effect Effects 0.000 description 7
- 238000010521 absorption reaction Methods 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 210000002200 mouth mucosa Anatomy 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 229920002498 Beta-glucan Polymers 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 4
- 239000003443 antiviral agent Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 240000002505 Pogostemon cablin Species 0.000 description 3
- 235000011751 Pogostemon cablin Nutrition 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000002865 immune cell Anatomy 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000003928 nasal cavity Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000037831 Polygonatum sibiricum Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 229920000392 Zymosan Polymers 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- YHAJBLWYOIUHHM-GUTXKFCHSA-N delta-guaiene Chemical compound C1C[C@@H](C(C)=C)C[C@H]2[C@@H](C)CCC2=C1C YHAJBLWYOIUHHM-GUTXKFCHSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- GGHMUJBZYLPWFD-UHFFFAOYSA-N patchoulialcohol Chemical compound C1CC2(C)C3(O)CCC(C)C2CC1C3(C)C GGHMUJBZYLPWFD-UHFFFAOYSA-N 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical group [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- XURCUMFVQKJMJP-UHFFFAOYSA-N Dihydro-alpha-guaien Natural products C1C(C(C)C)CCC(C)C2=C1C(C)CC2 XURCUMFVQKJMJP-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- GGHMUJBZYLPWFD-MYYUVRNCSA-N Patchouli alcohol Natural products O[C@@]12C(C)(C)[C@H]3C[C@H]([C@H](C)CC1)[C@]2(C)CC3 GGHMUJBZYLPWFD-MYYUVRNCSA-N 0.000 description 1
- 241000756042 Polygonatum Species 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- ADIDQIZBYUABQK-UHFFFAOYSA-N alpha-Guaiene Natural products C1C(C(C)=C)CCC(C)C2=C1C(C)CC2 ADIDQIZBYUABQK-UHFFFAOYSA-N 0.000 description 1
- ADIDQIZBYUABQK-RWMBFGLXSA-N alpha-guaiene Chemical compound C1([C@H](CC[C@H](C2)C(C)=C)C)=C2[C@@H](C)CC1 ADIDQIZBYUABQK-RWMBFGLXSA-N 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- YHAJBLWYOIUHHM-UHFFFAOYSA-N delta-guaiene Natural products C1CC(C(C)=C)CC2C(C)CCC2=C1C YHAJBLWYOIUHHM-UHFFFAOYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000001571 immunoadjuvant effect Effects 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 230000036046 immunoreaction Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000005007 innate immune system Anatomy 0.000 description 1
- -1 inorganic elements Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229930013686 lignan Natural products 0.000 description 1
- 150000005692 lignans Chemical class 0.000 description 1
- 235000009408 lignans Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 150000005856 steroid saponins Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 238000005556 structure-activity relationship Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 208000020017 viral respiratory tract infection Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 229930000038 α-guaiene Natural products 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/532—Agastache, e.g. giant hyssop
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Physiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to the technical field of medicine spray processing, and discloses an immune activation spray and a preparation method thereof. The spray for activating immunity comprises rhizoma Polygonati, oleum herba Pogostemonis, Atractylodis rhizoma, Borneolum Syntheticum, yeast and related emulsifier, cosolvent, and antiseptic. The dosage of each raw material is as follows according to the parts by weight: 25-35 parts of rhizoma polygonati; 0.05 to 0.1 portion of patchouli oil; 15-25 parts of bighead atractylodes rhizome; 0.01-0.06 part of borneol; 3-7 parts of yeast; proper amount of related emulsifier, cosolvent, preservative, etc. The immune activation spray provided by the invention is prepared by combining Chinese herbal medicines and yeast compounds, can give full play to multiple ways and multiple targets of medicines, comprehensively exerts the prevention and intervention of the Chinese herbal medicines, improves the immunity of the organism and improves the disease resistance of the organism.
Description
Technical Field
The invention belongs to the technical field of medicine spray processing, and relates to an immune activation spray and a preparation method thereof.
Background
Infectious diseases caused by viruses are a serious threat to human life and health. Statistically, more than 80% of infectious diseases are caused by viruses. Viral diseases have been implicated in various areas of clinical medicine and many non-infectious diseases have been found to be associated with viral infections, some of which are still associated with certain neoplastic and autoimmune diseases. Thus, viruses and diseases caused by the viruses are hot spots of much subject attention. The most common of viral infections are those caused by respiratory and enteric viruses. Respiratory viruses are a large group of viruses which can invade the respiratory tract and cause local lesions of the respiratory tract or only take the respiratory tract as an invasion portal, and firstly proliferate in the mucosal epithelial cells of the respiratory tract to cause respiratory tract and systemic infection, thereby causing lesions of the respiratory tract and related tissues and organs. Respiratory viruses are the major pathogens responsible for acute respiratory infections. Since the 90 s in the 20 th century, researchers found many new antiviral drugs, and the number of antiviral drugs currently used in clinic exceeds more than 20, but the exact curative effect is still greatly controversial. The research on the antiviral drug has important practical significance, and the research on finding the antiviral drug with high efficiency, safety and less side effects is imperative. The universality of diseases caused by viruses, particularly respiratory viruses, and the severity of damages caused by the diseases are always research hotspots, although western antiviral medicines are effective in treating the diseases, the toxic and side effects are large, drug resistance is easy to generate after long-term administration, and virus strains can also be changed into new drug-resistant strains due to variation, so that the clinical application of the existing western antiviral medicines and the research and development of new western antiviral medicines face huge challenges, and the vaccine can only temporarily and unstably treat the high-variability viruses, so that the search for traditional Chinese medicines with remarkable curative effect, small toxic and side effects and wide antiviral spectrum is still the research focus of the inventor.
The immune system is an important defense line against pathogen infection, the attack is actually the result of struggle between the pathogen and the human immunity, and the pathogen breaks the defense line of the immune system to cause rapid propagation of virus or bacteria, thus causing the occurrence of diseases. The immune function of the organism can be promoted and regulated as soon as possible, the anti-infection capability of the organism can be enhanced, and the anti-infection health-care tea has important significance for preventing and controlling diseases.
The traditional Chinese medicine is a natural medicine with a long use history for human beings, and contains various effective components capable of enhancing the immune function of organisms. The traditional Chinese medicine has the advantages of rich resources, small toxic and side effects, insignificant drug resistance, various performances and the like, contains various active ingredients for enhancing the immune function of organisms, and can be combined into various compounds according to the needs, so that the traditional Chinese medicine has wide and selective clinical application.
In recent years, researches on antiviral effects of plant polysaccharides have been receiving more and more attention. Polysaccharides are important biological information macromolecules and widely exist in animals, plants and microorganisms. At present, the regulation and control effect of polysaccharide on the body immune system is generally accepted by academia. The polysaccharide as an immunomodulator has the advantages of good curative effect, low toxicity and the like, and can act on an immune system through a plurality of ways, such as stimulating the differentiation and proliferation of various immunocompetent cells of an organism; promoting expression of various receptor molecules; inducing the production of cytokines such as Interleukin (IL), Tumor Necrosis Factor (TNF) and Interferon (IFN); promoting antibody formation; activation of complement system activation pathways, and the like. Modern molecular immunology studies have found that modulating the immune response of the body by ingestion of natural active substances is the most promising immunoadjuvant for replacement and adjuvant antibiotic therapy. Polysaccharide is one of important active ingredients in traditional Chinese medicines, at present, polysaccharide preparations such as astragalus polysaccharide injection, ginseng polysaccharide injection, pachyman oral liquid and the like are widely applied to clinic, but no polysaccharide spray is clinically available, and particularly no traditional Chinese medicine polysaccharide and zymosan compound spray is available.
Therefore, there is a need to develop a polysaccharide immune activation spray and a preparation method thereof, which are used for activating and improving the immunity of the organism and preventing and treating virus infection.
Disclosure of Invention
In order to overcome the defects of the prior art, the invention provides an immune activation spraying agent and a preparation method thereof. Compared with the injection, the immune activation spray provided by the invention has the characteristics of convenient administration, wide antiviral spectrum, small toxic and side effects, remarkable curative effect, rich medicine sources and low price.
The above purpose of the invention is realized by the following technical scheme:
an immunity activating spray comprises rhizoma Polygonati, oleum herba Pogostemonis, Atractylodis rhizoma, Borneolum Syntheticum, yeast and related emulsifier, cosolvent, and antiseptic.
The dosage of each raw material is as follows according to the parts by weight: 25-35 parts of rhizoma polygonati; 0.05 to 0.1 portion of patchouli oil; 15-25 parts of bighead atractylodes rhizome; 0.01-0.06 part of borneol; 3-7 parts of yeast; 0.5 to 1.2 portions of related emulsifier, 0.4 to 1.0 portion of cosolvent and 0.05 to 0.3 portion of preservative.
The emulsifier is polysorbate 80; the cosolvent is ethanol; the preservative is potassium sorbate.
The preparation method of the immune activation spraying agent comprises the following steps:
1) cleaning rhizoma Polygonati decoction pieces, adding water, extracting, and filtering to obtain rhizoma Polygonati extract;
2) cleaning Atractylodis rhizoma decoction pieces, adding water, extracting, and filtering to obtain Atractylodis rhizoma extract;
3) mixing rhizoma Polygonati leaching solution and Atractylodis rhizoma leaching solution, centrifuging, and concentrating to obtain rhizoma Polygonati and Atractylodis rhizoma concentrated solution;
4) adding cosolvent into Borneolum Syntheticum to obtain Borneolum Syntheticum solution;
5) adding emulsifier into oleum herba Pogostemonis to obtain oleum Pogostemonis emulsion;
6) preparing yeast suspension for later use;
7) dissolving the preservative to obtain a preservative solution for later use;
8) mixing rhizoma Polygonati and Atractylodis rhizoma concentrated solution, Borneolum Syntheticum solution, herba Agastaches oil emulsion, yeast suspension, and antiseptic solution, metering volume, sterilizing, and packaging to obtain the spray.
Further, the yeast is saccharomyces cerevisiae.
Further, the preparation process of the yeast suspension comprises the following steps:
a) cleaning rhizoma Polygonati decoction pieces, adding water, extracting, and filtering to obtain rhizoma Polygonati extract; the leaching conditions were: the material-water ratio of the rhizoma polygonati decoction pieces to water is 1: 100-120, soaking for 4-6 hours, leaching for 2 times with hot water at 98-100 ℃ for 1-2 hours each time, and filtering with 200 meshes to obtain sealwort leaching liquor.
b) Cleaning Atractylodis rhizoma decoction pieces, adding water, extracting, and filtering to obtain Atractylodis rhizoma extract; the leaching conditions were: the material-water ratio of the atractylodes macrocephala decoction pieces to water is 1: 100-120, soaking for 4-6 hours, leaching for 2 times with hot water at 98-100 ℃ for 1-2 hours each time, and filtering with 200 meshes to obtain a bighead atractylodes rhizome leaching solution;
c) mixing rhizoma Polygonati leaching solution and Atractylodis rhizoma leaching solution, concentrating, adding glucose to dissolve, diluting to constant volume to obtain yeast culture solution, sterilizing, cooling, inoculating yeast, fermenting and amplifying to obtain yeast fermentation liquid;
d) and (3) carrying out centrifugal concentration on the yeast fermentation liquor to obtain yeast (wet weight), wherein the weight ratio of the yeast to the liquid is 1: 1 in the presence of a yeast suspension.
The yeast culture solution comprises the following raw materials in parts by weight: 0.5-2 parts of rhizoma polygonati decoction pieces; 0.5-1 part of bighead atractylodes rhizome decoction pieces; 1-5 parts of glucose; 95-99 parts of water.
In the step 1) of the preparation method of the immune activation spraying agent, the leaching conditions are as follows: the material-water ratio of the rhizoma polygonati decoction pieces to water is 1: 10-20, soaking for 4-6 hours, leaching for 2 times with hot water at 98-100 ℃ for 1-2 hours each time, and filtering with 200 meshes to obtain sealwort leaching liquor.
In step 2) of the preparation method of the immune activation spraying agent, the leaching conditions are as follows: the material-water ratio of the atractylodes macrocephala decoction pieces to water is 1: 10-15, soaking for 4-6 hours, leaching for 2 times with hot water at 98-100 ℃ for 1-2 hours each time, and filtering with 200 meshes to obtain a white atractylodes rhizome leaching liquor.
In step 3) of the preparation method of the immune activation spraying agent, the method comprises the following steps: mixing rhizoma Polygonati leaching solution and Atractylodis rhizoma leaching solution, centrifuging at 12000 and 16000rpm tube or butterfly type, and concentrating the obtained liquid under reduced pressure.
Compared with the prior art, the invention has the beneficial effects that:
the immune activation spray provided by the invention can be sprayed to oral cavity and nasal cavity, is used for oral cavity and nasal cavity administration, can prevent the medicine from being degraded in gastrointestinal tract or due to liver metabolism, can promote the quick absorption of the medicine, improves the bioavailability, and plays a localized and directional local effect. Compared with an injection, the immune activation spraying agent provided by the invention has the characteristic of convenient administration.
The immune activation spray provided by the invention is prepared by compounding and combining rhizoma polygonati, bighead atractylodes rhizome, yeast, borneol and patchouli oil, accords with the theory of traditional Chinese medicine and modern pharmacology, and is mainly used for preventing viral respiratory tract infection. Different structure-activity relationships of various active polysaccharides such as polygonatum polysaccharides, atractylodes polysaccharides, zymosan and the like are combined and utilized, the anti-inflammatory and antiviral effects of patchouli oil are assisted, the mucosal absorption is promoted through the transdermal promoting effect of borneol, the respiratory tract mucosal immunoreaction is activated through multiple ways, the immunity of the organism is comprehensively and comprehensively improved, and the purpose of preventing viruses from infecting respiratory tracts is achieved.
The immune activation spray provided by the invention can act on respiratory tract mucous membrane, stimulate local mucous membrane immunity to generate secretory IgA, enhance the function of the pharyngeal mucous membrane immunity of organisms for resisting virus, and inhibit virus adsorption and invasion, thereby achieving the effects of prevention and treatment, achieving the purpose of preventing diseases before first and preventing diseases after recovery, and having important significance for preventing respiratory tract virus infection.
The immune activation spray provided by the invention is prepared by combining Chinese herbal medicines and yeast compounds, can give full play to multiple ways and multiple targets of medicines, comprehensively exerts the prevention and intervention of the Chinese herbal medicines, improves the immunity of the organism and improves the disease resistance of the organism.
The immune activation spraying agent provided by the invention has the advantages of abundant medicinal sources, simple and quick preparation method, contribution to batch production, low cost and certain social and economic values.
Polygonatum sibiricum (Polygonatum sibiricum), a perennial herbal plant of Liliaceae, which is widely used in traditional Chinese medicine clinical medicine since ancient times, has been 2000 years ago to date. Modern researches show that rhizoma polygonati contains various chemical components such as polysaccharide, oligosaccharide, flavone, steroid saponin, alkaloid, lignan, amino acid, inorganic elements, volatile oil and the like. The rhizoma Polygonati polysaccharide is the main active ingredient of rhizoma Polygonati, and has the pharmacological effects of regulating immunity, resisting bacteria and virus, diminishing inflammation, resisting aging, reducing blood sugar, reducing blood lipid, resisting atherosclerosis, and treating diabetes.
Atractylodis rhizoma belongs to perennial herb of Compositae and Atractylodes. In recent years, research shows that: the rhizoma Atractylodis Macrocephalae contains abundant polysaccharides, saponins, volatile oils, amino acids, and other effective components, which can act on digestive system, immune system, urinary system, etc. Wherein, the Atractylodes macrocephala Polysaccharide (PAM) is one of the main bioactive components of the Atractylodes macrocephala, is commonly used as an immunomodulator of an organism, has the functions of resisting oxidation, resisting aging, reducing blood sugar, resisting tumor, acting on myocardial cells and the like, and is clinically used for treating diseases such as hepatitis, tumor and the like. The atractylodes macrocephala polysaccharide can coordinate and play a role in regulating immunity of an organism through three levels of regulating immune organs, immune cells and immune molecules, not only acts on specific immunity of the organism, but also acts on non-specific immunity of the organism, and plays a role in regulating immunity of normal and abnormal organisms.
The β -glucan has the most basic function of immunoregulation, and the β -glucan can stimulate the innate immune system so as to achieve the purpose of greatly improving the capability of resisting bacteria, fungi, viruses and the like through in vivo and in vitro experimental researches, β -glucan can stimulate the differentiation and activation of T lymphocytes by activating T cells, macrophages and natural killer cells, influence and activate the change of pathway complements and finally achieve the effect of enhancing the cellular and humoral immunity of organisms, β -glucan in the yeast cell wall can act on receptors on the surface of immune cells so as to activate immune related signal transduction pathways, promote the immune cells to release downstream signal molecules and induce the organisms to generate nonspecific and specific immune response.
Borneol is a traditional Chinese medicine, also called borneol and 2-borneol, and modern research shows that the borneol belongs to a small molecular fat-soluble monoterpene substance and has pharmacological activities of promoting medicine absorption, protecting cardiovascular and cerebrovascular vessels, protecting central nerves, resisting bacteria, diminishing inflammation, easing pain, resisting fertility and the like. Borneol transdermal promotion mainly changes the lipid molecular arrangement of the stratum corneum of the skin to increase fluidity. The borneol reaching a certain concentration can promote the nasal cavity absorption, oral mucosa absorption and intestinal section absorption of the medicine. The barrier action of the oral mucosa is the most important influencing factor of the oral mucosa drug delivery system, and can block the drugs from entering the blood circulation of a human body through the oral mucosa. The application of the penetration enhancer borneol can promote the medicine to penetrate through oral mucosa and has small irritation to the mucosa.
Patchouli oil (Patchouli oil) is volatile oil extracted from Patchouli by a steam distillation method, and the main active ingredients of the Patchouli oil are Patchouli alcohol, Patchouli, α -guaiene, delta-guaiene, α -Patchouli, β -Patchouli, Patchouli ketone, tularenone and the like.
Detailed Description
The invention is described in more detail below with reference to specific examples, without limiting the scope of the invention. Unless otherwise specified, the experimental methods adopted by the invention are all conventional methods, and experimental equipment, materials, reagents and the like used in the experimental method can be obtained from commercial sources.
Example 1
An immunity activating spray comprises rhizoma Polygonati, oleum herba Pogostemonis, Atractylodis rhizoma, Borneolum Syntheticum, yeast and related emulsifier, cosolvent, and antiseptic.
The dosage of each raw material is as follows according to the parts by weight: 25 parts of rhizoma polygonati; 0.05 part of patchouli oil; 15 parts of bighead atractylodes rhizome; 0.01 part of borneol; 3 parts of yeast; proper amount of related emulsifier, cosolvent, preservative, etc.
The preparation method of the immune activation spraying agent comprises the following steps:
1) cleaning rhizoma Polygonati decoction pieces, adding water, extracting, and filtering to obtain rhizoma Polygonati extract;
2) cleaning Atractylodis rhizoma decoction pieces, adding water, extracting, and filtering to obtain Atractylodis rhizoma extract;
3) mixing rhizoma Polygonati leaching solution and Atractylodis rhizoma leaching solution, centrifuging, and concentrating to obtain rhizoma Polygonati and Atractylodis rhizoma concentrated solution;
4) adding cosolvent into Borneolum Syntheticum to obtain Borneolum Syntheticum solution;
5) adding emulsifier into oleum herba Pogostemonis to obtain oleum Pogostemonis emulsion;
6) preparing yeast suspension for later use;
7) dissolving the preservative to obtain a preservative solution for later use;
8) mixing rhizoma Polygonati and Atractylodis rhizoma concentrated solution, Borneolum Syntheticum solution, herba Agastaches oil emulsion, yeast suspension, and antiseptic solution, metering volume, sterilizing, and packaging to obtain the spray.
Further, the yeast is saccharomyces cerevisiae.
Further, the preparation process of the yeast suspension comprises the following steps:
a) cleaning rhizoma Polygonati decoction pieces, adding water, extracting, and filtering to obtain rhizoma Polygonati extract; the leaching conditions were: the material-water ratio of the rhizoma polygonati decoction pieces to water is 1: 100, soaking for 4 hours, leaching for 2 times with hot water at 98 ℃ for 1 hour each time, and filtering with 200 meshes to obtain rhizoma polygonati leaching liquor.
b) Cleaning Atractylodis rhizoma decoction pieces, adding water, extracting, and filtering to obtain Atractylodis rhizoma extract; the leaching conditions were: the material-water ratio of the atractylodes macrocephala decoction pieces to water is 1: 100, soaking for 4 hours, leaching for 2 times with hot water at 98 ℃ for 1 hour each time, and filtering with 200 meshes to obtain a white atractylodes rhizome leaching liquor;
c) mixing rhizoma Polygonati leaching solution and Atractylodis rhizoma leaching solution, concentrating, adding glucose to dissolve, diluting to constant volume to obtain yeast culture solution, sterilizing, cooling, inoculating yeast, fermenting and amplifying to obtain yeast fermentation liquid;
d) and (3) carrying out centrifugal concentration on the yeast fermentation liquor to obtain yeast (wet weight), wherein the weight ratio of the yeast to the liquid is 1: 1 in the presence of a yeast suspension.
The yeast culture solution comprises the following raw materials in parts by weight: 0.5 part of sealwort decoction pieces; 0.5 part of bighead atractylodes rhizome decoction pieces; 1 part of glucose; and 95 parts of water.
In the step 1) of the preparation method of the immune activation spraying agent, the leaching conditions are as follows: the material-water ratio of the rhizoma polygonati decoction pieces to water is 1: 10, soaking for 4 hours, leaching for 2 times with hot water at 98 ℃ for 1 hour each time, and filtering with 200 meshes to obtain rhizoma polygonati leaching liquor.
In step 2) of the preparation method of the immune activation spraying agent, the leaching conditions are as follows: the material-water ratio of the atractylodes macrocephala decoction pieces to water is 1: 10, soaking for 4 hours, leaching for 2 times with hot water at 98 ℃ for 1 hour each time, and filtering with 200 meshes to obtain a white atractylodes rhizome leaching liquor.
In step 3) of the preparation method of the immune activation spraying agent, the method comprises the following steps: mixing rhizoma Polygonati leaching solution and Atractylodis rhizoma leaching solution, centrifuging at 16000rpm, centrifuging to obtain liquid, and concentrating under reduced pressure.
Example 2
An immunity activating spray comprises rhizoma Polygonati, oleum herba Pogostemonis, Atractylodis rhizoma, Borneolum Syntheticum, yeast and related emulsifier, cosolvent, and antiseptic.
The dosage of each raw material is as follows according to the parts by weight: 35 parts of rhizoma polygonati; 0.1 part of patchouli oil; 25 parts of bighead atractylodes rhizome; 0.06 part of borneol; 7 parts of yeast; proper amount of related emulsifier, cosolvent, preservative, etc.
The preparation method of the immune activation spraying agent comprises the following steps:
1) cleaning rhizoma Polygonati decoction pieces, adding water, extracting, and filtering to obtain rhizoma Polygonati extract;
2) cleaning Atractylodis rhizoma decoction pieces, adding water, extracting, and filtering to obtain Atractylodis rhizoma extract;
3) mixing rhizoma Polygonati leaching solution and Atractylodis rhizoma leaching solution, centrifuging, and concentrating to obtain rhizoma Polygonati and Atractylodis rhizoma concentrated solution;
4) adding cosolvent into Borneolum Syntheticum to obtain Borneolum Syntheticum solution;
5) adding emulsifier into oleum herba Pogostemonis to obtain oleum Pogostemonis emulsion;
6) preparing yeast suspension for later use;
7) dissolving the preservative to obtain a preservative solution for later use;
8) mixing rhizoma Polygonati and Atractylodis rhizoma concentrated solution, Borneolum Syntheticum solution, herba Agastaches oil emulsion, yeast suspension, and antiseptic solution, metering volume, sterilizing, and packaging to obtain the spray.
Further, the yeast is saccharomyces cerevisiae.
Further, the preparation process of the yeast suspension comprises the following steps:
a) cleaning rhizoma Polygonati decoction pieces, adding water, extracting, and filtering to obtain rhizoma Polygonati extract; the leaching conditions were: the material-water ratio of the rhizoma polygonati decoction pieces to water is 1: 120, soaking for 6 hours, leaching for 2 times with hot water at 100 ℃ for 2 hours each time, and filtering with 200 meshes to obtain rhizoma polygonati leaching liquor.
b) Cleaning Atractylodis rhizoma decoction pieces, adding water, extracting, and filtering to obtain Atractylodis rhizoma extract; the leaching conditions were: the material-water ratio of the atractylodes macrocephala decoction pieces to water is 1: 120, soaking for 6 hours, leaching for 2 times with hot water at 100 ℃ for 2 hours each time, and filtering with 200 meshes to obtain a white atractylodes rhizome leaching liquor;
c) mixing rhizoma Polygonati leaching solution and Atractylodis rhizoma leaching solution, concentrating, adding glucose to dissolve, diluting to constant volume to obtain yeast culture solution, sterilizing, cooling, inoculating yeast, fermenting and amplifying to obtain yeast fermentation liquid;
d) and (3) carrying out centrifugal concentration on the yeast fermentation liquor to obtain yeast (wet weight), wherein the weight ratio of the yeast to the liquid is 1: 1 in the presence of a yeast suspension.
The yeast culture solution comprises the following raw materials in parts by weight: 2 parts of rhizoma polygonati decoction pieces; 1 part of bighead atractylodes rhizome decoction pieces; 5 parts of glucose; and 99 parts of water.
In the step 1) of the preparation method of the immune activation spraying agent, the leaching conditions are as follows: the material-water ratio of the rhizoma polygonati decoction pieces to water is 1: 20, soaking for 6 hours, leaching for 2 times with hot water at 100 ℃ for 2 hours each time, and filtering with 200 meshes to obtain rhizoma polygonati leaching liquor.
In step 2) of the preparation method of the immune activation spraying agent, the leaching conditions are as follows: the material-water ratio of the atractylodes macrocephala decoction pieces to water is 1: 15, soaking for 6 hours, leaching for 2 times with hot water at 100 ℃ for 2 hours each time, and filtering with 200 meshes to obtain the rhizoma atractylodis macrocephalae leaching liquor.
In step 3) of the preparation method of the immune activation spraying agent, the method comprises the following steps: mixing rhizoma Polygonati leaching solution and Atractylodis rhizoma leaching solution, centrifuging at 12000rpm, centrifuging to obtain liquid, and concentrating under reduced pressure.
Example 3
An immunity activating spray comprises rhizoma Polygonati, oleum herba Pogostemonis, Atractylodis rhizoma, Borneolum Syntheticum, yeast and related emulsifier, cosolvent, and antiseptic.
The dosage of each raw material is as follows according to the parts by weight: 30 parts of rhizoma polygonati; 0.08 part of patchouli oil; 20 parts of bighead atractylodes rhizome; 0.03 part of borneol; 5 parts of yeast; proper amount of related emulsifier, cosolvent, preservative, etc.
The preparation method of the immune activation spraying agent comprises the following steps:
1) cleaning rhizoma Polygonati decoction pieces, adding water, extracting, and filtering to obtain rhizoma Polygonati extract;
2) cleaning Atractylodis rhizoma decoction pieces, adding water, extracting, and filtering to obtain Atractylodis rhizoma extract;
3) mixing rhizoma Polygonati leaching solution and Atractylodis rhizoma leaching solution, centrifuging, and concentrating to obtain rhizoma Polygonati and Atractylodis rhizoma concentrated solution;
4) adding cosolvent into Borneolum Syntheticum to obtain Borneolum Syntheticum solution;
5) adding emulsifier into oleum herba Pogostemonis to obtain oleum Pogostemonis emulsion;
6) preparing yeast suspension for later use;
7) dissolving the preservative to obtain a preservative solution for later use;
8) mixing rhizoma Polygonati and Atractylodis rhizoma concentrated solution, Borneolum Syntheticum solution, herba Agastaches oil emulsion, yeast suspension, and antiseptic solution, metering volume, sterilizing, and packaging to obtain the spray.
Further, the yeast is saccharomyces cerevisiae.
Further, the preparation process of the yeast suspension comprises the following steps:
a) cleaning rhizoma Polygonati decoction pieces, adding water, extracting, and filtering to obtain rhizoma Polygonati extract; the leaching conditions were: the material-water ratio of the rhizoma polygonati decoction pieces to water is 1: 150, soaking for 5 hours, leaching for 2 times with hot water at 100 ℃ for 1.5 hours each time, and filtering with 200 meshes to obtain rhizoma polygonati leaching liquor.
b) Cleaning Atractylodis rhizoma decoction pieces, adding water, extracting, and filtering to obtain Atractylodis rhizoma extract; the leaching conditions were: the material-water ratio of the atractylodes macrocephala decoction pieces to water is 1: 110, soaking for 5 hours, leaching for 2 times with hot water at 100 ℃ for 1.5 hours each time, and filtering with 200 meshes to obtain a white atractylodes rhizome leaching liquor;
c) mixing rhizoma Polygonati leaching solution and Atractylodis rhizoma leaching solution, concentrating, adding glucose to dissolve, diluting to constant volume to obtain yeast culture solution, sterilizing, cooling, inoculating yeast, fermenting and amplifying to obtain yeast fermentation liquid;
d) and (3) carrying out centrifugal concentration on the yeast fermentation liquor to obtain yeast (wet weight), wherein the weight ratio of the yeast to the liquid is 1: 1 in the presence of a yeast suspension.
The yeast culture solution comprises the following raw materials in parts by weight: 1 part of rhizoma polygonati decoction pieces; 0.8 part of bighead atractylodes rhizome decoction pieces; 3 parts of glucose; and 96 parts of water.
In the step 1) of the preparation method of the immune activation spraying agent, the leaching conditions are as follows: the material-water ratio of the rhizoma polygonati decoction pieces to water is 1: 15, soaking for 5 hours, leaching for 2 times with hot water at 100 ℃ for 1.5 hours each time, and filtering with 200 meshes to obtain rhizoma polygonati leaching liquor.
In step 2) of the preparation method of the immune activation spraying agent, the leaching conditions are as follows: the material-water ratio of the atractylodes macrocephala decoction pieces to water is 1: 12, soaking for 5 hours, leaching for 2 times with hot water at 100 ℃ for 1.5 hours each time, and filtering with 200 meshes to obtain the rhizoma atractylodis macrocephalae leaching liquor.
In step 3) of the preparation method of the immune activation spraying agent, the method comprises the following steps: mixing rhizoma Polygonati leaching solution and Atractylodis rhizoma leaching solution, centrifuging at 12000rpm, centrifuging to obtain liquid, and concentrating under reduced pressure.
The rhizoma polygonati leaching liquor, the rhizoma atractylodis macrocephalae leaching liquor and the yeast suspension prepared in the embodiment all contain the active ingredient polysaccharide.
The embodiments described above are merely preferred embodiments of the invention, rather than all possible embodiments of the invention. Any obvious modifications to the above would be obvious to those of ordinary skill in the art, but would not bring the invention so modified beyond the spirit and scope of the present invention.
Claims (8)
1. An immune activation spray is characterized by comprising rhizoma polygonati, patchouli oil, bighead atractylodes rhizome, borneol, yeast and related emulsifying agents, cosolvents and preservatives.
2. The immune activation spray as claimed in claim 1, wherein the dosage of each raw material is as follows by weight: 25-35 parts of rhizoma polygonati; 0.05 to 0.1 portion of patchouli oil; 15-25 parts of bighead atractylodes rhizome; 0.01-0.06 part of borneol; 3-7 parts of yeast.
3. The method for preparing an immune-activating spray according to claim 1 or 2, which comprises the steps of:
1) cleaning rhizoma Polygonati decoction pieces, adding water, extracting, and filtering to obtain rhizoma Polygonati extract;
2) cleaning Atractylodis rhizoma decoction pieces, adding water, extracting, and filtering to obtain Atractylodis rhizoma extract;
3) mixing rhizoma Polygonati leaching solution and Atractylodis rhizoma leaching solution, centrifuging, and concentrating to obtain rhizoma Polygonati and Atractylodis rhizoma concentrated solution;
4) adding cosolvent into Borneolum Syntheticum to obtain Borneolum Syntheticum solution;
5) adding emulsifier into oleum herba Pogostemonis to obtain oleum Pogostemonis emulsion;
6) preparing yeast suspension for later use;
7) dissolving the preservative to obtain a preservative solution for later use;
8) mixing rhizoma Polygonati and Atractylodis rhizoma concentrated solution, Borneolum Syntheticum solution, herba Agastaches oil emulsion, yeast suspension, and antiseptic solution, metering volume, sterilizing, and packaging to obtain the spray.
4. The method of preparing an immune-activating spray according to claim 3, wherein the yeast is Saccharomyces cerevisiae.
5. The method of preparing an immune-activating spray according to claim 3, wherein the yeast suspension is prepared by the steps of:
a) cleaning rhizoma Polygonati decoction pieces, adding water, extracting, and filtering to obtain rhizoma Polygonati extract; the leaching conditions were: the material-water ratio of the rhizoma polygonati decoction pieces to water is 1: 100-120, soaking for 4-6 hours, leaching for 2 times with hot water at 98-100 ℃ for 1-2 hours each time, and filtering with 200 meshes to obtain rhizoma polygonati leaching liquor;
b) cleaning Atractylodis rhizoma decoction pieces, adding water, extracting, and filtering to obtain Atractylodis rhizoma extract; the leaching conditions were: the material-water ratio of the atractylodes macrocephala decoction pieces to water is 1: 100-120, soaking for 4-6 hours, leaching for 2 times with hot water at 98-100 ℃ for 1-2 hours each time, and filtering with 200 meshes to obtain a bighead atractylodes rhizome leaching solution;
c) mixing rhizoma Polygonati leaching solution and Atractylodis rhizoma leaching solution, concentrating, adding glucose to dissolve, diluting to desired volume, sterilizing, cooling, inoculating yeast, fermenting and amplifying to obtain yeast fermentation liquid;
d) and (3) carrying out centrifugal concentration on the yeast fermentation liquor to obtain yeast and liquid with the weight ratio of 1: 1 in the presence of a yeast suspension.
6. The method for preparing an immune-activating spray according to claim 3, wherein the leaching conditions in step 1) are as follows: the material-water ratio of the rhizoma polygonati decoction pieces to water is 1: 10-20, soaking for 4-6 hours, leaching for 2 times with hot water at 98-100 ℃ for 1-2 hours each time, and filtering with 200 meshes to obtain sealwort leaching liquor.
7. The method for preparing an immune-activating spray according to claim 3, wherein the leaching conditions in step 2) are as follows:
the material-water ratio of the atractylodes macrocephala decoction pieces to water is 1: 10-15, soaking for 4-6 hours, leaching for 2 times with hot water at 98-100 ℃ for 1-2 hours each time, and filtering with 200 meshes to obtain a white atractylodes rhizome leaching liquor.
8. The method for preparing an immune-activating spray according to claim 3, wherein the step 3) comprises the steps of:
mixing rhizoma Polygonati leaching solution and Atractylodis rhizoma leaching solution, and centrifuging at 12000 and 16000 rpm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010242232.3A CN111358891A (en) | 2020-03-31 | 2020-03-31 | Immune activation spray and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010242232.3A CN111358891A (en) | 2020-03-31 | 2020-03-31 | Immune activation spray and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111358891A true CN111358891A (en) | 2020-07-03 |
Family
ID=71199134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010242232.3A Pending CN111358891A (en) | 2020-03-31 | 2020-03-31 | Immune activation spray and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111358891A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110123946A (en) * | 2019-05-21 | 2019-08-16 | 四川农业大学 | A kind of process using saccharomyces cerevisiae solid state fermentation rhizoma polygonati |
-
2020
- 2020-03-31 CN CN202010242232.3A patent/CN111358891A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110123946A (en) * | 2019-05-21 | 2019-08-16 | 四川农业大学 | A kind of process using saccharomyces cerevisiae solid state fermentation rhizoma polygonati |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111358891A (en) | Immune activation spray and preparation method thereof | |
| CN104436145A (en) | Pharmaceutical composition for preventing and/or treating allergic rhinitis and allergic asthma | |
| CN112755102A (en) | Pharmaceutical composition for treating piglet diarrhea, traditional Chinese medicine granules and preparation method thereof | |
| CN113318158A (en) | A topical composition for treating rhinitis and preparation method thereof | |
| CN1054035C (en) | Health cigarette containing Chinese herbal medicine | |
| CN109908109A (en) | A kind of anti-inflammatory analgesic emplastrum and preparation method thereof | |
| CN111419894A (en) | Pharmaceutical composition for reducing uric acid and preparation method thereof | |
| CN116211993B (en) | Composition for treating senile chronic disease and its preparation method | |
| CN112107645B (en) | Traditional Chinese medicine composition for improving reproductive function and improving quality of life | |
| CN116849357B (en) | Medicinal and edible composition with liver protection function and preparation method thereof | |
| CN114796293B (en) | Application of hederagenin C | |
| Xiao et al. | Pharmacology, pharmacokinetics and toxicology of Chinese traditional medicine for stroke therapy | |
| CN117085091B (en) | A Chinese medicinal composition for treating cardiovascular diseases | |
| CN114949114B (en) | Agilawood-containing traditional Chinese medicine composition for enhancing immunity as well as preparation method, preparation and application thereof | |
| CN105560907A (en) | Local wet compressing preparation capable of relieving postpartum pain | |
| CN114425058B (en) | Traditional Chinese medicine composition for treating rhinitis and preparation method, medicine and preparation thereof | |
| CN109528957A (en) | It is a kind of to have effects that protect the compound Chinese medicinal preparation and preparation method thereof of stomach | |
| CN112402565B (en) | Traditional Chinese medicine composition for treating gonarthromeningitis and preparation method thereof | |
| CN110812451B (en) | Pain arthralgia pill and preparation method and application thereof | |
| CN112402566B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating gonarthromeningitis | |
| CN101721450A (en) | Application of oriental cocklebur root chloroform extract used for treating peritonitis | |
| CN118615359A (en) | Composition for treating allergic rhinitis and preparation method and application thereof | |
| CN107041907A (en) | A kind of compound preparation of Urtica macrorrhiza Hand.-Mazz extract and fevervine extract | |
| CN118750559A (en) | Traditional Chinese medicine composition for treating children cold and cough as well as preparation method and application thereof | |
| CN106421154A (en) | Traditional Chinese medicine composition and traditional Chinese medicine preparation containing Chinese eaglewood wood and having cell repairing, anti-aging and anti-canter functions as well as preparation method of traditional Chinese medicine composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200703 |